We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$445M
AUM Growth
+$21.4M
Cap. Flow
-$18.8M
Cap. Flow %
-4.22%
Top 10 Hldgs %
46.96%
Holding
84
New
14
Increased
27
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$9.12M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.93M
4
VCYT icon
Veracyte
VCYT
+$5.3M
5
PCVX icon
Vaxcyte
PCVX
+$5.23M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$16.6M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.83M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.76M
4
NUVL
Nuvalent
NUVL
+$7.82M
5
URGN icon
UroGen Pharma
URGN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
51
Trevi Therapeutics
TRVI
$2.61B
$1.61M 0.36%
482,575
-361,660
-43% -$1.08M
XNCR icon
52
Xencor
XNCR
$1.59B
$1.52M 0.34%
+75,507
New +$1.42M
TARS icon
53
Tarsus Pharmaceuticals
TARS
$2.6B
$1.32M 0.3%
40,000
– –
KOD icon
54
Kodiak Sciences
KOD
$2.66B
$1.3M 0.29%
500,000
-562,062
-53% -$1.49M
EVGN icon
55
Evogene
EVGN
$5.92M
$945K 0.21%
307,974
– –
MTEM
56
DELISTED
Molecular Templates, Inc.
MTEM
$876K 0.2%
623,838
– –
CCCC icon
57
CALL
C4 Therapeutics
CCCC
$405M
$855K 0.19%
150,000
– –
APLT
58
DELISTED
Applied Therapeutics
APLT
$850K 0.19%
+100,000
New +$589K
VXRT
59
DELISTED
Vaxart
VXRT
$849K 0.19%
+1,000,000
New +$764K
EYPT icon
60
EyePoint Inc
EYPT
$1.08B
$799K 0.18%
100,000
– –
ASND icon
61
Ascendis Pharma A/S
ASND
$16.5B
$747K 0.17%
+5,000
New +$675K
TIL icon
62
Instil Bio
TIL
$48.4M
$708K 0.16%
+10,517
New +$248K
ETNB
63
DELISTED
89bio
ETNB
$683K 0.15%
92,298
– –
KPTI icon
64
Karyopharm Therapeutics
KPTI
$159M
$464K 0.1%
37,231
– –
BDTX icon
65
Black Diamond Therapeutics
BDTX
$98.6M
$435K 0.1%
+100,000
New +$544K
GUTS icon
66
Fractyl Health
GUTS
$109M
$422K 0.09%
166,666
– –
CRBP icon
67
CALL
Corbus Pharmaceuticals
CRBP
$168M
$367K 0.08%
+17,800
New +$911K
MRSN
68
CALL
DELISTED
Mersana Therapeutics
MRSN
$318K 0.07%
6,732
– –
ALGS icon
69
Aligos Therapeutics
ALGS
$26.7M
$227K 0.05%
26,219
-2
-0% -$25
YARW
70
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
$144K 0.03%
1,536
-7,812
-84% -$740K
RCKTW icon
71
Rocket Pharmaceuticals Warrant
RCKTW
$342K
$6.76K ﹤0.01%
104,828
– –
ALXO icon
72
PUT
ALX Oncology
ALXO
$262M
– –
-167,900
Closed -$1.01M
CRBP icon
73
Corbus Pharmaceuticals
CRBP
$168M
– –
-172,492
Closed -$8.83M
ENGN icon
74
enGene Therapeutics
ENGN
$118M
– –
-263,841
Closed -$2.49M
FULC icon
75
Fulcrum Therapeutics
FULC
$248M
– –
-398,436
Closed -$2.47M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Silverarc Capital Management held 84 positions worth $445M, up 5.1% from $424M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Silverarc Capital Management withdrew a net $18.8M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Centessa Pharmaceuticals worth $11.9M.

  • Silverarc Capital Management's largest Q3 2024 buy was Centessa Pharmaceuticals: 744,592 shares worth $11.9M.
  • Silverarc Capital Management added most to Insmed in Q3 2024, an estimated $15.3M increase.
  • Silverarc Capital Management's biggest Q3 2024 reduction was Celldex Therapeutics, cutting an estimated $8.76M.
  • Silverarc Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $16.6M.
  • Silverarc Capital Management's ten largest holdings make up 47% of its $445M portfolio in Q3 2024.
  • Silverarc Capital Management opened 14 new positions and closed 13 in Q3 2024.
  • Silverarc Capital Management's portfolio value rose 5.1% quarter-over-quarter to $445M.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.